A disciplined, highly targeted approach to discovering new cancer medicines
Rigorous, definitive clinical trials based on deep biology and chemistry expertise
Committed to bringing differentiated new cancer medicines to patients
ARIAD's first internally discovered and developed medicine
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
A shared commitment to patients and each other. This is ARIAD.
click here for PDF